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Abstract
The known breast cancer susceptibility genes only account for 20% to 25% of the excess familial risk of the
disease [1]. The present study assessed the contribution of BRCA1/2 mutations and CHEK2 variants to the
relative risk of breast cancer for women with affected mothers or sisters. The familial relative risks were estimated
by Poisson regression based on the Swedish Family-Cancer Database. The Database was also used to calculate
the distribution of life expectancy, the number of daughters per family and the age specific cumulative risk of
female breast cancer. This information, together with the penetrances of BRCA1, BRCA2 and CHEK2 from the
literature, was used to simulate the familial clustering of breast cancer under different scenarios. The excess risk
explained by BRCA1, BRCA2 and CHEK2 decreased steeply with the age at diagnosis of the cancers. Around
40% of the familial risk for cases diagnosed before the age of 50 years was associated with BRCA1/2 mutations.
In contrast, roughly 85% of the familial risk of breast cancer diagnosed before the age of 69 years remained
unexplained. The contribution of CHEK2 to familial breast cancer was small. 
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Introduction
Breast cancer aggregates in families, the disease
being about twice as common in mothers and sisters
of cases as it is in the general population [2]. The
higher risks of breast cancer for monozygotic than for
dizygotic twins of cases suggest that the familial
aggregation of breast cancer is mainly due to genetic
effects, rather than to shared environmental factors [3].
Germline mutations in BRCA1 and BRCA2 are
frequently found in families containing multiple
individuals affected by breast cancer [4]. However,
BRCA1 and BRCA2 mutations are only identified in
about 15-20% of multiple-case families affected by
breast cancer alone [5]. CHEK2*1100delC, 
a truncating variant that abrogates the kinase activity
of CHEK2 [6], has been also found to contribute
significantly to the familial clustering of breast cancer
[7]. The variant has shown a frequency of 1.1% in
healthy individuals and it has been associated with 
a breast cancer risk ratio of 1.7 in families without
BRCA1/2 mutations. By contrast, the variant conferred
no increased cancer risk in carriers of BRCA1/2
mutations. The low proportion of familial breast
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cancers attributable to known genes, from 20% to 25%
[1], reflects major gaps in our knowledge of the genetic
background of familial breast cancer. 
In addition to the age, sex and genotype specific
penetrance, the family history of breast cancer is
influenced by demographic factors such as family size
and mortality [8]. The aim of the present study was to
assess the contribution of the BRCA1/2 mutations and
CHEK2 variants to the relative risk of breast cancer for
women with affected mothers or sisters. We used the
Swedish Family-Cancer (SFC) Database to estimate the
distribution of life expectancy, the number of daughters
per family and the age specific cumulative risk of
female breast cancer in Sweden. The penetrances
associated with BRCA1/2 and CHEK2 were taken from
the literature. This information was used to simulate
the familial clustering of breast cancer under different
scenarios.  
Patients and methods
The Swedish Family-Cancer Database was created
in mid 1990s by linking census information, death
notifications and the administrative family registry at
Statistics Sweden to the Swedish Cancer Registry. The
Database was updated at the end of 2002 to include
more than 10.34 million individuals born in Sweden
after 1931 as well as more than 810,000 invasive
cancers diagnosed after 1958. The Swedish Cancer
Registry is based on separate compulsory notifications
of cases from clinicians/pathologists or cytologists and
is considered to have completeness close to 100% [9].
The incidence of cancer in the Database is similar to
the incidence in the Cancer Registry [10, 11]. Data on
parity were complete, information on the
socioeconomic index and the region was based on
population censuses from 1960, 1970, 1980 and
1990. The age of the women in the first generation
(mothers) was unrestricted, but the maximum age of
women in the second generation (daughters) was 68
years. The present study included 20,742 cases of
invasive breast cancer among 3.25 million daughters
and 67,575 cases of invasive breast cancer among
2.23 million mothers.
Poisson regression
The relative risk of breast cancer for daughters
(RRmother) and sisters (RRsister) of Swedish women affected
by breast cancer was estimated by Poisson regression.
The women in the SFC Database were followed from
birth, immigration date or 1961, whichever came
latest, until diagnosis of breast cancer, death,
emigration date or 31 December 2000. The incidence
of breast cancer was explained by the variables: age 
(5-year bands), period (10-year bands), parity (six
groups from ‘any parturition’ to ‘more than five
parturitions’), socioeconomic status (six groups), age
at first birth (five groups, 5-year bands between ‘before
age of 20’ and ‘after age of 35’) and residential area
(four groups). The analyses were carried out for
different restrictions of the age at diagnosis of breast
cancer, which varied from 50 to 69 years.
Computations were performed with the SAS software
using the procedure GENMOD. 
Simulation
The SFC Database was used to estimate the
cumulative risks of female breast cancer before specific
ages. The incidences in BRCA1/2 mutation carriers
reported by Antoniou et al [12] were transformed into
cumulative risks by the formula: cumulative risk (%) =
100•(1-exp [0.05•Σxi]), where Σxi was the sum of the
five-year incidences before the age under
consideration. The cumulative risks before the age of
69 years were calculated by linear interpolation. The
cumulative risks from the SFC Database, the cumulative
risks for BRCA1/2 mutation carriers from the literature
and the prevalences of BRCA1/2 mutations found by
Loman et al among affected Swedish women [13] were
used to estimate the frequency of BRCA1/2 mutations
in Sweden. For example, the cumulative risk of female
breast cancer before the age of 40 years of 0.31%,
the cumulative risk of breast cancer by the age of 40
years in BRCA1 mutation carriers of 11.57% and the
prevalence of BRCA1 mutation carriers in women
affected by breast cancer before the age of 40 years
of 7.26%, would result in a frequency of BRCA1
mutations in Sweden of 0.098%. The prevalence and
penetrance of CHEK2 variants were based on the study
of the CHEK2 Breast Cancer Consortium [7]. The
distribution of the number of daughters per family and
the distribution of life expectancy were calculated using
the SFC Database. 
The distribution of family size was used to generate
one hundred million nuclear families. The genotypes of
the parents were created by using the calculated
prevalences of BRCA1/2 mutations and the frequency
of CHEK2 variants from the literature. One allele was
taken at random from each parent in order to simulate
the genotypes of the daughters, under the assumption
that women carrying two copies of one mutated genes
were nonviable. The individual’s age at death was
generated by using the distribution of life expectancy
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from the SFC Database. The phenotype of each woman
(affected or unaffected) was conditional on her genotype
and her age at death. The familial aggregation of breast
cancer was explored under different scenarios. The
simplest scenario included only one gene; the most
elaborated model considered simultaneously BRCA1,
BRCA2 and CHEK2. The simulated disease phenotypes
were used to calculate the relative risks for daughters
and sisters of affected women. 
The proportion of familial relative risk attributable
to BRCA1, BRCA2 and CHEK2 was assessed by
comparing the results from the Poisson regression with
the data from the simulation. The formula:
100•(RRBRCA1/2,CHEK2 -1)/(RRmother -1) was used to
calculate the percentage of maternal excess risk
attributable to the three genes, where RRBRCA1/2,CHEK2
was the estimated relative risk for daughters of affected
women when the simulation included the BRCA1,
BRCA2 and CHEK2 genes, and RRmother was the relative
risk for daughters of affected women estimated by the
Poisson regression based on the SFC Database. Similar
calculations were carried out to assess the contribution
of BRCA1, BRCA2 and CHEK2 to the relative risk for
sisters of affected women.
Results
The cumulative risks of breast cancer used in the
simulation are presented in Table 1. Based on the SFC
Database, 0.003% of the women had breast cancer
by the age of 25 years and 6.48% of them were
affected before the age of 69 years. The penetrances
of BRCA1/2 mutations estimated by Antoniou et al [12]
are also shown in Table 1. These were 63% for women
who carried BRCA1 mutations and 42% for BRCA2
mutations carriers by the age of 69 years. The
distribution of the number of daughters in the SFC
Database was as follows: 68% of the families had one
daughter, 26% had two daughters, 5% had three
daughters and 1% of the families had four or more
daughters. The calculated distribution of life expectancy
is shown in Table 1; 77.3% of the women reached the
age of 69 years. The cumulative risks of breast cancer
from the SFC Database and previous data from the
literature resulted in an estimated prevalence of BRCA1
mutations in Sweden of 0.098%, whereas the estimated
prevalence of BRCA2 mutations was 0.052%. Following
the study of the CHEK2 Breast Cancer Consortium,
1.1% of the simulated individuals were CHEK2
mutation carriers [7]. These data were taken into
account to generate the phenotype distribution of 
a large population, which was utilized to compute the
familial risk of breast cancer under different scenarios. 
The relative risks of breast cancer for women with
affected mothers based on the SFC Database are
shown in Fig. 1. The RRmother was 2.11 (95%CI: 1.85-
2.41) for breast cancers diagnosed before the age of
50 years, and it decreased to 1.56 (95%CI: 1.46-1.66)
Table 1. Cumulative risk of breast cancer in Sweden, penetrance of BRCA1 and BRCA2 mutations based on the literature and life expectancy
of Swedish women*
Cumulative risk of breast cancer (%) % alive
by age all women BRCA1 mutation carriers BRCA2 mutation carriers
25 0.003  0.10 0.10 99.1
30 0.02 0.65 0.70 98.8
35 0.09 4.26 2.47 98.4
40 0.31 11.57 6.20 97.7
45 0.85 23.59 10.37 96.5
50 1.74 38.31 16.18 94.3
55 2.95 45.96 23.05 90.5
60 4.26 53.51 30.55 85.9
65 5.59 59.38 38.61 80.5
69 6.48 62.73 42.25 77.3
*[12]; see Patients and methods for details
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for cancers under the age of 65 years. The scenario
‘cancer occurs due to CHEK2 mutations’ led to
estimates of the RRmother practically identical to unity.
When only BRCA2 mutations were considered, the
estimated RRmother decreased from 1.04 (breast cancers
before the age of 50 years) to 1.01 (cancers before
the age of 69 years). The scenario ‘cancer is
attributable BRCA1 mutations’ showed the RRmother of
1.43 (cancers diagnosed before the age of 50 years)
and the RRmother of 1.07 (cancers before the age of 69
years). The maternal risks under the scenario ‘BRCA1
and BRCA2 mutations’ were similar to those after the
simultaneous consideration of BRCA1, BRCA2 and
CHEK2 mutations; the RRmother was 1.47 for breast
cancer before the age of 50 years and 1.09 for breast
cancer before the age of 69 years. 
The RRsister from the Poisson regression decreased
from 2.19 (95%CI: 1.98-2.43), for breast cancers
diagnosed before the age of 50 years, to 1.97
(95%CI: 1.86-2.09), for cancers diagnosed before the
age of 60 years (Fig. 2). The scenario ‘only BRCA2
mutations’ resulted in the RRsister of 1.02 (breast cancers
diagnosed before the age of 50 years) and the RRsister
of 1.01 (cancers before the age of 69 years). BRCA1
mutations showed the RRsister of 1.41 for breast cancers
diagnosed before the age of 50 years, and the RRsister
of 1.06 for cancers before the age of 69 years. The
results for BRCA1 and BRCA2 mutations were similar
to the results for BRCA1, BRCA2 and CHEK2; the
RRsister was 1.46 for breast cancer diagnosed before
the age of 50 years and it was 1.08 for cancers before
the age of 69 years.   
The excess risk explained by BRCA1, BRCA2 and
CHEK2 decreased with increasing ages at diagnosis
and it was higher for daughters than for sisters of
affected women. For example, 14% of the relative risk
for daughters of women affected by the age of 69
years was related to BRCA1, BRCA2 and CHEK2
mutations, but the corresponding proportion for sisters
of affected women was only around 8%. 
Discussion
The most direct way to address the question
concerning the existence of other breast cancer
susceptibility genes is to ask whether the known genes
can explain the observed familial aggregation of
breast cancer [1]. Germline mutations in the p53,
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Fig. 1. Relative risk of breast cancer for daughters of women with breast cancer in Sweden and effect of BRCA1, BRCA2 and CHEK2
mutations on the relative risk of breast cancer for daughters of affected women. Both the cases and the probands are restricted to the
indicated age 
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PTEN, STK11/LKB1 and ATM genes are rare in familial
breast cancer [14]. The present study assessed the
contribution of BRCA1, BRCA2 and CHEK2 to the
relative risk of breast cancer. The estimated familial
risks for Swedish women relied entirely on registered
data of complete coverage. Other important features
of this study were the large number of cases analyzed,
the standardization for parity and age of first birth,
and the inclusion of information on family size and life
expectancy in the simulation. The age of the
individuals from the first generation in the SFC
Database was unrestricted, but the maximum age of
the individuals in the second generation (68 years)
was a limitation on the present study. 
Mutations in BRCA1 and BRCA2 show considerable
ethnic and geographic variation [15]. Specific BRCA1 or
BRCA2 mutations have become common as a result of
founder effects in Ashkenazi Jewish populations [15-17],
Poland [18], Iceland [19] and the European part of Russia
[20]. The contribution of BRCA1 and BRCA2 to familial
breast cancer in those populations is likely to be more
important than in Sweden. The mutation prevalences
assumed in this study, 0.098% for BRCA1 and 0.052%
for BRCA2, were calculated using the SFC Database and
the Swedish results of Lohman et al [13]. These
prevalences are in agreement with the literature, e.g.
Easton proposed frequencies between 0.05% and 0.20%
for both BRCA1 and BRCA2 [1] and Domchek et al
estimated a prevalence of BRCA1 mutations of 0.125%
[21]. The prevalence and penetrance assumed for CHEK2
variants may be more inaccurate. This study concentrated
on the 1100delC frameshift mutation and was based on
the results from the CHEK2-Breast Cancer Consortium,
but the same conclusions were reached by using German
[22] or Finish [23] data (results not shown).
The estimated risks were higher for sisters than for
daughters of affected women, and the difference
between the two familial relative risks increased with
the age at diagnosis of breast cancer. Several studies
have suggested that this difference is mostly attributable
to the unequal number of parturitions and the different
calendar year of diagnosis of mothers and sisters [2,
24]. Since 97% of the analyzed daughters were parous,
the contribution of parity to the difference of relative
risks, if any, should be small. In contrast, the median
calendar year of diagnosis of mothers was 1971 and
that of sisters - 1996. The establishment of screening
services in Sweden has resulted in the earlier detection
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Fig. 2. Relative risk of breast cancer for sisters of women with breast cancer in Sweden and effect of BRCA1, BRCA2 and CHEK2 mutations
on the relative risk of breast cancer for sisters of affected women. Both the cases and the probands are restricted to the indicated age  
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of breast cancers [25] and may have also affected the
detection of familial cancers. 
In contrast to the familial relative risks estimated by
the Poisson regression, the relative risks associated with
BRCA1 and BRCA2 mutations in the simulation were
slightly lower for sisters than for mothers of affected
women, especially when the cancers were diagnosed
before the age of 50 years. The separate analysis of
each gene showed that BRCA1 mutations would
explain 34% to 39% of the familial relative risk by the
age of 50 years, the corresponding figure would be
2% to 4% for BRCA2 mutations, and less than 1% of
the familial risk was attributable to CHEK2 variants. 
In conclusion, the proportion of excess familial risk due to
BRCA1/2 mutations cited in the literature of about 15% [26],
varies considerably with the population and the age at diagnosis
of the cancers. In Sweden roughly 40% of the familial relative
risk for breast cancers diagnosed before the age of 50 years
is likely to be associated with BRCA1/2 mutations, but around
85% of the excess risk remains unexplained when all cancers
diagnosed before the age of 69 years are considered. The
proportion of familial excess attributable to CHEK2 variants, or
other low susceptibility genes, is small. 
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